Huaiyuan (Henry) Zhang
About Huaiyuan (Henry) Zhang
Huaiyuan (Henry) Zhang is a Scientist II currently employed at Johnson & Johnson Innovative Medicine. He has a strong academic background in biological sciences, holding a Ph.D. from the Illinois Institute of Technology and experience in various research roles.
Current Role at Serotiny
Huaiyuan (Henry) Zhang currently serves as Scientist II at Serotiny, a position he has held since 2022. He works in South San Francisco, California, contributing to the company's innovative projects in the field of biotechnology. His role involves applying his extensive knowledge in cellular and molecular biology to advance research and development efforts.
Previous Experience at Johnson & Johnson
Before his current role at Serotiny, Huaiyuan Zhang worked at Johnson & Johnson Innovative Medicine as Scientist II. He joined the company in 2024 and has been involved in various projects aimed at developing new medical solutions. His tenure at Johnson & Johnson follows his significant experience in research and development in the biotechnology sector.
Research Background at Illinois Institute of Technology
Huaiyuan Zhang spent five years at the Illinois Institute of Technology, where he conducted research as a PhD researcher from 2016 to 2021. His research focused on cellular and molecular biology, contributing to advancements in the field. Additionally, he served as a teaching assistant during his time at the institution, further enhancing his academic and practical knowledge.
Educational Qualifications
Huaiyuan Zhang holds a Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology from the Illinois Institute of Technology, which he completed from 2016 to 2021. Prior to this, he earned a Master of Science (M.S.) in Biology/Biological Sciences from the same institution between 2014 and 2016. He also holds a Bachelor of Science (B.S.) in Biotechnology from Jilin University, completed from 2008 to 2013.
Experience at Sorrento Therapeutics
Huaiyuan Zhang worked as a Scientist at Sorrento Therapeutics, Inc. for six months in 2021 to 2022. During his time there, he focused on research initiatives aimed at developing therapeutic solutions. This experience added to his expertise in the biotechnology field and prepared him for subsequent roles in his career.